Charles Mango, MD
Ophthalmology · Bronxville, NYNPI 1528025129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 28.0% of the total.
Across 112 payments — averaging $37.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$813
- Genentech USA, Inc.$519
- Astellas Pharma US Inc$416
- Dutch Ophthalmic, USA$402
- Eyepoint US, Inc.$271
- plus $601 from 12 others
What the payments were for
- Food & beverage$4,200100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 49 | $1,178 |
| AbbVie(2 entities) | 14 | $813 |
| Genentech USA, Inc. | 8 | $519 |
| Astellas Pharma US Inc | 13 | $416 |
| Dutch Ophthalmic, USA | 3 | $402 |
| Eyepoint US, Inc. | 2 | $271 |
| Carl Zeiss Meditec, Inc. | 2 | $127 |
| Novartis | 6 | $98 |
| Mallinckrodt Hospital Products Inc. | 2 | $73 |
| Biogen | 3 | $63 |
| Harrow Eye, LLC | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Apellis Pharmaceuticals, Inc. | 1 | $33 |
| Coherus Oncology, Inc. | 1 | $25 |
| Alimera Sciences, Inc. | 1 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$434
- EVA, combined machine$283
- Lucentis$273
- YUTIQ$271
- TISSUEBLUE$164
- VABYSMO$149
- EYLEA$124
- EVA Ophthalmic Surgical System$119
- Izervay$108
How this compares
$4,200 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 26 | $1,271 |
| Ketorolac Tromethamine | 31 | $1,019 |
| Timolol Maleate | 13 | $310 |
| Latanoprost | 18 | $287 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bronxville
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.